Metformin Class Action Canada

Rice Harbut Elliott LLP is investigating a possible class action lawsuit, representing Canadians who were prescribed metformin containing a nitrosamine impurity called N-nitrosodimethylamine (NDMA) above the acceptable limit.  Drugs containing metformin are used to treat patients with diabetes.  At present, the recall involves the following metformin products:


Company Product name/Active Pharmaceutical Ingredient (API) DIN Strength Lot # Expiry
Apotex Inc. APO-Metformin ER (Metformin Hydrochloride Extended-Release Tablets) 02305062 500 mg NV3242 04/2020
NV3244 04/2020
NV3245 04/2020
NV3243 04/2020
NV3247 04/2020
NV3248 04/2020
PX5334 01/2021
PX5335 01/2021
Ranbaxy Pharmaceuticals Canada Inc. RAN-Metformin 02269031 500 mg AJY8006A 05/2020
500 mg AJY8007A 05/2020
500 mg AJY8005A 05/2020
500 mg AJY8005B 05/2020
500 mg AJY8008A 05/2020
850 mg AJY8005A 05/2020

The full details of the Health Canada recall can be found  here.

Our firm is seeking compensation for persons who received any of the above-listed drugs.  Damages will be sought for individuals who were diagnosed with cancer and other individuals who received the drugs that were recalled.  The latter group may be entitled to compensation pursuant to B.C. consumer protection legislation.

If you received any of the above-listed drugs, you may be affected by this class action lawsuit. Please fill out the form below to get in touch with us. Joining our contact list creates no financial obligation and we will keep all the information that you provide to us confidential.

If you have any recalled Metformin please preserve it as we may wish to arrange testing to determine the levels of toxins in the medication.


Who qualifies for this Class Action?

Canadians who purchased and ingested Metformin on the recall list –


Objectives of Class Action?

Compensation for personal injury or refunds for persons who purchased and/or ingested recalled Metformin